The Science of Longevity: Evidence-Based Interventions from Clinical Research

Welcome to "The Science of Longevity," a podcast dedicated to exploring the latest evidence-based research on aging, lifespan extension, and healthspan improvement. We move beyond speculation to analyze peer-reviewed clinical studies and rigorous scientific evidence published within the last decade.

Episode Focus: From Hallmarks to Human Trials

The field is currently at an exciting inflection point, with multiple human clinical trials underway targeting fundamental aging mechanisms, such as cellular senescence, mitochondrial dysfunction, NAD+ decline, and accumulated DNA damage.

What we cover in this episode:

• The Realistic Goal: We explore why the realistic promise of current longevity research is primarily extended healthspan—achieving more years of healthy, functional life and delaying the onset of aging-related diseases—rather than expecting dramatic lifespan increases in the near term. It is important to note that there is no proven drug or supplement that extends human lifespan demonstrated in a long-term human randomized controlled trial.
• Rapamycin and mTOR Inhibitors: Learn about the most studied potential longevity intervention, rapamycin, which inhibits the mTORC1 pathway. While every preclinical study has shown that rapamycin extends mouse lifespan in at least one dosing group, early human evidence suggests benefits for immune function.
• Metformin and Longevity Candidates: We discuss the observational evidence suggesting that longevity candidates like metformin and Vitamin D may significantly reduce all-cause mortality and prolong life expectancy. Metformin is currently being rigorously tested in the landmark Targeting Aging with Metformin (TAME) trial.
• Cellular Cleanup: Senolytics and NAD+ Boosters: We dive into interventions targeting cellular decline, including senolytics (like dasatinib combined with quercetin), which selectively eliminate senescent "zombie cells" implicated in frailty. Additionally, we review the robust human safety data on NAD+ precursors (NMN and nicotinamide riboside), which show efficacy for metabolic improvements and increased physical performance in older adults.
• Emerging Geroprotectors: Urolithin A: We review the evidence on Urolithin A (UA), a gut metabolite derived from foods like pomegranate and walnut, being assessed for its potential geroprotective effect in humans. Recent systematic reviews covering five studies involving 250 healthy individuals indicate that UA (10–1000 mg/day) showed a dose-dependent anti-inflammatory effect and increased muscle strength and endurance. However, UA did not affect physical function, anthropometrics, cardiovascular outcomes, or maximal ATP production in these studies.

Join us as we assess the efficacy, safety, and future directions of these promising interventions, providing you with evidence-informed insights into how to improve your healthspan.